MedTrace Logo

Prospective Evaluation of SARS-CoV-2 Antibodies Levels in a Vaccinated Population of Valle de Aburra

NCT05172167 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-03-02

No results posted yet for this study

Summary

Recent research evidence shows that levels of antibodies acquierd post vacunation against SARS-Cov-2 decrease over time as well as the efficacy to control the infection, additionally in a multicenter study carried out in 2020 were evidenced differences in the time it took to decrease the antibodies according to the type of vaccine, defined as mRNA or other types of vaccine.

In this study , the variation of the SARS-Cov-2 antibody levels in patients from Valle de Aburrá will be correlated according to the COVID-19 vaccine received.

Conditions

Interventions

DIAGNOSTIC_TEST

Levels of IgG and IgM SARS-CoV-2 antibodies blood test.

0,1,2 months

DIAGNOSTIC_TEST

RT-PCR SARS-CoV-2 nasopharyngeal swab

0,1,2 months

Sponsors & Collaborators

  • Laboratorio integrado de medicina especializada(LIME)

    collaborator UNKNOWN

  • Proyecto de regalias BPIN 2020000100152

    collaborator UNKNOWN

  • Universidad de Antioquia

    lead OTHER

Principal Investigators

  • Andres F Zuluaga, MD, MSc, MeH · Universidad de Antioquia

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-02
Primary Completion
2022-04-15
Completion
2022-04-30

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172167 on ClinicalTrials.gov